Functional Dyspepsia Clinical Trial
Official title:
The Effect of Ginger on Functional Dyspepsia Symptoms and Body Fat Content Among Patients With Functional Dyspepsia
Verified date | April 2024 |
Source | University of Debrecen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to assess ginger's effect on patients with functional dyspepsia. The main question[s] it aims to answer are: 1. Does ginger intake improve functional dyspepsia symptoms? 2. Does ginger intake decrease the body fat content among patients with functional dyspepsia? Dyspepsia patients will be asked to take 540 mg of ginger capsule twice a day. Researchers will assess if there is an improvement in the symptoms of the disease and the fat content. [ to see if gingers effect.
Status | Enrolling by invitation |
Enrollment | 62 |
Est. completion date | December 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 72 Years |
Eligibility | Inclusion Criteria: - Patients suffering from Functional dyspepsia symptoms Exclusion Criteria: - Patients with relevant gastroesophageal reflux symptoms (retrosternal pain, burning, or regurgitation) as well as patients with clear evidence of irritable bowel syndrome will not be included. Patients under treatment with pharmacological substances that could influence the gastrointestinal system, such as prokinetics, ursodeoxycholic acid (UDCA), nonsteroidal anti-inflammatory drugs (NSAIDs), cholagogues, protonpump inhibitors, and H2 blockers, will be asked to interrupt this treatment for one month before starting the study treatment. Moreover, patients with a previous diagnosis of cancer or with previous surgery of the upper gastrointestinal tract or of the biliopancreatic system (except for cholecystectomy) and patients with active HP infection or with gastric or duodenal ulcer, as well as pregnant women, will be excluded. |
Country | Name | City | State |
---|---|---|---|
Hungary | University of Debrecen | Debrecen |
Lead Sponsor | Collaborator |
---|---|
University of Debrecen |
Hungary,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Dyspepsia Symptom Severity | This study will evaluate and measure the expected improvements in functional dyspepsia symptoms. It will be assessed by the Nepean Dyspepsia Index (NDI) questionnaire, among 62 patients with functional dyspepsia treated with ginger supplementation compared to the baseline, by the end of the four-week intervention. This measure focuses on the reduction in symptoms such as pain, discomfort, bloating, and early satiety. Each item on the Nepean Dyspepsia Index questionnaire is usually scored on a Likert scale, with higher scores representing more severe symptoms or greater impairment. I.e. Higher scores on the Nepean Dyspepsia Index indicate more severe dyspeptic symptoms and a greater impact on quality of life. Lower scores indicate milder symptoms and less impairment in quality of life. Therefore, a reduction in Nepean Dyspepsia Index scores in response to ginger supplementation indicates an improvement in symptoms and quality of life for individuals with dyspepsia. | four weeks | |
Primary | Body Fat Content Analysis | Changes in body fat content, which will be assessed before and after four weeks of ginger supplementation using the In-Body 270, a non-invasive device that measures body weight, skeletal muscle mass, body fat, and other health parameters at five body parts using two different frequencies. This measure aims to evaluate the impact of Functional Dyspepsia and ginger supplementation on body composition, which could be relevant due to potential associations between functional dyspepsia and alterations in body fat distribution. | Four weeks | |
Secondary | Improvement in Quality of Life | Improvements in quality of life will be assessed by the EuroQol Group's EQ-5D questionnaire before and after 4 weeks of ginger supplementation. EuroQol Group's EQ-5D consists of 2 main components:
Descriptive System: This part evaluates health status across 5 dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression Each is rated on a 3-level scale: 1: No problems to 3: Extreme problems Visual Analog Scale (VAS): Respondents rate on a scale from 0 to 100, where: 0: Represents the worst imaginable health state 100: Represents the best imaginable health state The values for EQ-5D ratings are as follows: For each dimension in the descriptive system, the minimum value is 1 (indicating no problems) and the maximum value is 3 (indicating extreme problems). For the VAS, the minimum value is 0 (worst imaginable health state) and the maximum value is 100 (best imaginable health state). |
Four weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04464369 -
Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial
|
Phase 4 | |
Completed |
NCT01671670 -
Acupuncture for Patients With Function Dyspepsia
|
Phase 2/Phase 3 | |
Completed |
NCT00987805 -
Efficacy of Banhasasim-tang on Functional Dyspepsia
|
Phase 4 | |
Completed |
NCT00693407 -
Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation
|
N/A | |
Completed |
NCT00761358 -
To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT01240096 -
Mirtazapine Versus Placebo in Functional Dyspepsia
|
Phase 4 | |
Recruiting |
NCT04540549 -
Effects of Exercise on Functional Dyspepsia Based on Rome IV
|
N/A | |
Recruiting |
NCT03652571 -
Nortriptyline for the Treatment of Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Recruiting |
NCT03825692 -
International Clinical Study of Zhizhu Kuanzhong Capsule
|
Phase 4 | |
Not yet recruiting |
NCT04548011 -
Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia
|
N/A | |
Terminated |
NCT02567578 -
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT03007433 -
Assessment of GI Function to a Large Test Meal by Non-invasive Imaging
|
N/A | |
Active, not recruiting |
NCT00990405 -
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
|
Phase 4 | |
Completed |
NCT00404534 -
Helicobacter Eradication Relief of Dyspeptic Symptoms
|
Phase 3 | |
Completed |
NCT03043625 -
Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia
|
N/A | |
Completed |
NCT03225248 -
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05587127 -
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT01021475 -
Does Visceral Manipulation Works in Treating Functional Dyspepsia?
|
Phase 1 |